分子亚型和瘤微环境 小细胞肺癌的特征 与抗性相关
Jihyun Kim1,2, Sunshin Kim1, Seog-Yun Park3
1Research Institute, National Cancer Center, 232 Ilsan-ro, Goyang-si 10408, Kyeonggi-do, Republic of Korea.
Cancers
|July 29, 2023
概括
确定了四种小细胞肺癌 (SCLC) 的分子亚型,揭示了不同治疗抗性的治疗和机制. 内皮转介质过渡 (EndMT) 与预后不佳和耐药性有关,这表明BET抑制剂是有前途的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症基因组学 癌症基因组学
背景情况:
- 小细胞肺癌 (SCLC) 的分子亚型尚未完全理解,这限制了临床相关性和治疗策略.
- 完善SCLC亚型和确定治疗点对于改善患者的治疗结果至关重要.
研究的目的:
- 改进SCLC的分子亚型,并确定新的治疗点.
- 研究瘤微环境 (TME) 和分子改变在SCLC发育和抗性中的作用.
主要方法:
- 对SCLC样本的基因表达概况 (n=81) 和验证 (n=87).
- 与非SCLC样本进行比较,以确定SCLC早期发育阶段.
- 对TME的单细胞转录组分析和对白金耐药性的药物查.
主要成果:
- 已经确定了四种SCLC亚型:ASCL1+ (SCLC-A),免疫激活 (SCLC-I),NEUROD1 (SCLC-N) 和POU2F3+ (SCLC-P).
- 在SCLC-I中,内皮转介质转变 (EndMT) 与预后不佳和抗性有关.
- 在SCLC-I中,BET抑制剂对侵袭性血管新生有显著的疗效.
结论:
- SCLC亚型表现出明显的分子特征和治疗脆弱性.
- 终端MT和TME异质性有助于SCLC中的抗性.
- BET抑制剂代表了克服SCLC中白金耐药性的新疗法策略.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
The Tumor Microenvironment
6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
